CULLINAN THERAPEUTICS

Cullinan Oncology to Host Analyst and Investor Briefing at 2022 ASCO Annual Meeting

26 May 2022 08:45:00 By Nasdaq GlobeNewswire

Cullinan Oncology to Present at H.C. Wainwright Global Investment Conference

19 May 2022 08:00:01 By Nasdaq GlobeNewswire

Cullinan Oncology Provides Corporate Update and Reports First Quarter 2022 Financial Results

16 May 2022 06:45:00 By Nasdaq GlobeNewswire

Cullinan Oncology and Taiho Pharmaceutical Announce Strategic Collaboration to Jointly Develop and Commercialize CLN-081/TAS6417 and Taiho’s Acquisition of Cullinan Pearl

12 May 2022 02:00:00 By Nasdaq GlobeNewswire

Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 May 2022 17:10:24 By Nasdaq GlobeNewswire

Cullinan Oncology to Present Updated Data Highlighting the Therapeutic Potential of CLN-081 in Patients with EGFR Exon 20 Insertion Mutation Positive Non-Small Cell Lung Cancer at the 2022 ASCO Annual Meeting

27 Apr 2022 10:00:00 By Nasdaq GlobeNewswire

Cullinan Oncology to Participate in Upcoming Virtual Healthcare Conferences

05 Apr 2022 08:00:01 By Nasdaq GlobeNewswire

Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 Apr 2022 16:34:22 By Nasdaq GlobeNewswire

Cullinan Oncology Announces Clinical and Regulatory Update for CLN-081 in NSCLC EGFR Exon 20 Patients

28 Mar 2022 16:01:00 By Nasdaq GlobeNewswire

Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results

17 Mar 2022 07:08:06 By Nasdaq GlobeNewswire

Cullinan Oncology to Host CLN-081 Regulatory Update Webinar on March 28, 2022

17 Mar 2022 07:00:01 By Nasdaq GlobeNewswire

Cullinan Oncology to Present at the Barclays Global Healthcare Conference

09 Mar 2022 08:00:02 By Nasdaq GlobeNewswire

Cullinan Oncology to Present Data Demonstrating Breadth and Progress of Its Immuno-Oncology Portfolio at AACR 2022

08 Mar 2022 17:30:00 By Nasdaq GlobeNewswire

Cullinan Oncology Expands Leadership Team and Board of Directors with Appointments of Jeffrey Jones, M.D., MPH, MBA to Chief Medical Officer and Anne-Marie Martin Ph.D. to Board of Directors

28 Feb 2022 08:00:01 By Nasdaq GlobeNewswire

Cullinan Oncology to Present at SVB Leerink’s 11th Annual Global Healthcare Conference

07 Feb 2022 06:30:00 By Nasdaq GlobeNewswire

Cullinan Oncology Forms Strategic Collaboration Agreement with Mount Sinai to Advance Oral HPK1 Protein Degrader for Cancer Treatment

10 Jan 2022 06:30:00 By Nasdaq GlobeNewswire

Cullinan Oncology to Present at Upcoming Virtual Investor Conferences

05 Jan 2022 09:00:02 By Nasdaq GlobeNewswire

FDA Grants Breakthrough Therapy Designation for Cullinan Oncology’s CLN-081 in Patients with Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer

04 Jan 2022 07:00:02 By Nasdaq GlobeNewswire

Cullinan Oncology Announces Updated Phase 1/2a Data for CLN-081 in NSCLC EGFR Exon 20 Patients

16 Dec 2021 06:30:00 By Nasdaq GlobeNewswire

Cullinan Oncology to Provide Clinical Update for CLN-081 in NSCLC EGFR Exon 20 Patients

13 Dec 2021 07:00:00 By Nasdaq GlobeNewswire